They only started selling commercially the last year. Sales are 40% more than the 1st six months of 2014. These seems like traction to me.
The past is the past. I'm looking at what they do beginning 01/01/14 and basing my opinions on that.
Good luck all.
Unfortunately they've gone to the well too many times and each time at a lower price. Will new investors actually be willing to supply funds when ROSG products have yet to generate meaningful revenue? Most biotechs see approved products as the target that will provide great returns to early investors. ROSG has had its tests on the market for years now and still can't get any traction.
Alas, too true, but that is always the case with microcap biotechnology stocks. The headwind they all face is the cash shortage for continuing operations, and ROSG is no different. No different, except that this company has products on the market, and the possibility of improving revenues might be enough to attract a major partner, and that would diminish the need for a secondary.
In the last month ROSG has issued several PRs that indicate good things from revenue standpoint are just around the corner. The question I have is whether there's enough cash to get us to the corner. It would seem that others feel the same way, with share lingering around 3. Implication is that another secondary will come out and until the price and dilution becomes public, caution is the key.
I'm just speculating. Until there is significant cash flow, even if not enough to continue funding of operations, share price will have a tough time getting back to the massive secondary we had at 5.
you're damn right they have, simply tearing up the markets.
Urologists also reported they would use a tool that could more accurately classify tumor subtype in 62% of cases, and 73% believe the performance characteristics matching the Rosetta Kidney Cancer Test’s performance provide sufficiently meaningful results to change treatment of RO patients
Gradual release of good news, letter to shareholders, time of year that biotechnology stocks do well, all are favorable for us in the coming months. Also, today's volume is relatively strong on this rise.
Seems like the kidney test will become a required standard of care to avoid medical and legal issues.
Sentiment: Strong Buy
Thanking longterm shareowners and recognizing our continuous committment to a management which has failed to keep place with the marketplace is admirable.
but lets face it... We invest to make money-
rosg has been a empty bag.
time to refocus efforts to reward longterm shareowners
its time to reward berlin!